Comparative Pharmacology
Head-to-head clinical analysis: ALDORIL D30 versus AMTURNIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDORIL D30 versus AMTURNIDE.
ALDORIL D30 vs AMTURNIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.
AMTURNIDE is a combination of amiloride, a potassium-sparing diuretic that inhibits sodium reabsorption in the distal convoluted tubule and collecting duct, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium chloride reabsorption in the distal convoluted tubule. The combination produces additive diuretic and antihypertensive effects with reduced potassium loss.
Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.
10 mg to 20 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life of hydrochlorothiazide is 6-15 hours; methyldopa half-life is 1.8 hours (normal renal function). In renal impairment, half-life of both components is prolonged.
Terminal elimination half-life is 12 hours (range 10–14 hours); steady-state achieved within 2–3 days.
Renal: approximately 50% as parent drug and metabolites; biliary/fecal: minimal, less than 5%.
Primarily renal excretion as unchanged drug (70%) and glucuronide conjugate (15%); biliary/fecal elimination accounts for 10%.
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination